- Home
- PC vs SNGX Comparison
PC vs SNGX Comparison
Compare PC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- SNGX
- Stock Information
- Founded
- PC 2012
- SNGX 1987
- Country
- PC Singapore
- SNGX United States
- Employees
- PC N/A
- SNGX N/A
- Industry
- PC Restaurants
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- SNGX Health Care
- Exchange
- PC Nasdaq
- SNGX Nasdaq
- Market Cap
- PC 11.1M
- SNGX 9.6M
- IPO Year
- PC 2024
- SNGX 1987
- Fundamental
- Price
- PC $0.73
- SNGX $3.51
- Analyst Decision
- PC
- SNGX
- Analyst Count
- PC 0
- SNGX 0
- Target Price
- PC N/A
- SNGX N/A
- AVG Volume (30 Days)
- PC 846.1K
- SNGX 56.4K
- Earning Date
- PC 11-26-2024
- SNGX 11-08-2024
- Dividend Yield
- PC N/A
- SNGX N/A
- EPS Growth
- PC N/A
- SNGX N/A
- EPS
- PC N/A
- SNGX N/A
- Revenue
- PC $3,809,288.00
- SNGX $364,183.00
- Revenue This Year
- PC N/A
- SNGX N/A
- Revenue Next Year
- PC N/A
- SNGX $76.64
- P/E Ratio
- PC N/A
- SNGX N/A
- Revenue Growth
- PC N/A
- SNGX N/A
- 52 Week Low
- PC $0.60
- SNGX $1.83
- 52 Week High
- PC $5.73
- SNGX $32.00
- Technical
- Relative Strength Index (RSI)
- PC N/A
- SNGX 49.14
- Support Level
- PC N/A
- SNGX $3.50
- Resistance Level
- PC N/A
- SNGX $3.74
- Average True Range (ATR)
- PC 0.00
- SNGX 0.20
- MACD
- PC 0.00
- SNGX 0.01
- Stochastic Oscillator
- PC 0.00
- SNGX 47.37
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).